CelcuityCELC
CELC logo
Fair Value
US$94
Share price19 Mar
US$115.7223.1% overvalued intrinsic discount
Loading
1Y763.58%
7D10.61%

Single Drug Dependence And Heavy Financing Will Shape A Challenging Future

Analyst Low Target compiles bearish analysts opinions to create narratives which represent one standard deviation below the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
19 Mar 26
Views
15
Not Invested

Fair Value vs Share Price

US$94
vs US$115.7223.1% overvalued intrinsic discount
PastFuture-127m414m2015201820212024202620272029Revenue US$414.4mEarnings US$129.7m
74.5k%
Revenue growth
31.3%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Celcuity

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

High growth potential with adequate balance sheet.

Market capUS$5.3b
PB105.4x
Estimated Growth53.0%
Dividend YieldN/A
Full analysis

CEO & management

Brian Sullivan
CEO
5.5yrs
CEO Tenure

A clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States.